Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within ...

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) plunged ~21% in the morning hours on Wednesday after the biotech fell short of ...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company reported ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 10.44%, which has investors questioning if this is right ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would ...

Tonix Pharmaceuticals has a one year low of $6.76 and a one year high of $1,170.24. The company has a market capitalization of $34.00 million, a PE ratio of 0.00 and a beta of 2.23.

Reports Q4 revenue $2.6M, consensus $3.35M.”With commercial preparations underway, we believe we are well positioned to launch TNX-102 SL for ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research ...

Shares of Tonix Pharmaceuticals Holding fell after the company logged lower sales and another net loss in the fourth quarter. The stock declined 6.9%, to $19.12, in after-hours trading Tuesday. Shares ...

TNX-102 SL was generally well tolerated and has no known addictive properties. Dr. Lederman continued, “Tonix is debt free and expects to have sufficient cash to fund operations through the ...

2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two ...

Ms. Fogarty originally joined Tonix in 2016 and has over 25 years of experience in pharmaceutical and biotech product development, manufacturing and quality, for both small and large molecules ...